Nurix Therapeutics Company Insiders

Nurix Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3108) % which means that it has lost $0.3108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6416) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics' management efficiency ratios could be used to measure how well Nurix Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nurix Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 75.6 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 185.2 M in 2025. Common Stock Shares Outstanding is likely to drop to about 44.6 M in 2025. Net Loss is likely to rise to about (154.2 M) in 2025

Nurix Therapeutics Workforce Comparison

Nurix Therapeutics Insider Trading

Nurix Therapeutics Notable Stakeholders

The success or failure of an entity such as Nurix Therapeutics often depends on how effective the management is. Nurix Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nurix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nurix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Nurix Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nurix Therapeutics. Check Nurix Therapeutics' Beneish M Score to see the likelihood of Nurix Therapeutics' management manipulating its earnings.

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.